Status:
UNKNOWN
Monitoring Efficacy of Radiotherapy in Lung Cancer and Esophageal Cancer
Lead Sponsor:
Chinese Academy of Medical Sciences
Conditions:
Lung Cancer
Esophageal Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Lung cancer, one of the malignant tumors which poses a threat to human's health, has increased morbidity and mortality recently. Radiotherapy, as one of the common treatments, has important value in c...
Detailed Description
Circulating free DNA (cfDNA) can be found dissolved in plasma and serum, at variable amounts. In the case of cancer patients, ctDNA is a fraction of the cfDNA derived from tumor. Currently, the ctDNA ...
Eligibility Criteria
Inclusion
- Patients with histopathological proved lung cancer or esophageal cancer.
- Candidate for radiotherapy.
- No history of prior anti-tumor treatment.
- Eastern Cooperative Oncology Group (ECOG) score 0,1.
- Being able to receive computed tomography (CT) and magnetic resonance imaging (MRI).
- Blood sample is available for dynamic monitoring.
- Written informed consent provided.
- Good compliance in the follow-up.
Exclusion
- Had received radiotherapy, chemotherapy, biotherapy or other treatment that is related to lung cancer or esophageal cancer.
- The patients have the sign of any serious or uncontrolled systematic diseases that may have significant impact on the balance between risk and benefit, such as hypertension, infection of hepatitis B, hepatitis C or human immunodeficiency virus(HIV).
- With history of alcohol or drug abuse.
Key Trial Info
Start Date :
February 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2022
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT04014465
Start Date
February 1 2019
End Date
December 1 2022
Last Update
February 2 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Radiation Oncology, Cancer Hospital, Chinese Academy of Medical sciences
Beijing, Beijing Municipality, China, 100021